Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment
Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment
复制标题
DOI：
10.1158/1078-0432.ccr-10-3366
复制
发表时间：
2011-03-15
影响因子：
11.5
通讯作者：
Anderson, Kenneth C.
中科院分区：
文献类型：
--
作者：
Anderson, Kenneth C.
多发性骨髓瘤（MM）是新药开发中快速从实验室到床边转化的一个例子。硼替佐米和来那度胺靶向骨髓微环境中的肿瘤细胞，以克服实验室和动物模型中的耐药性;每一种都能有效治疗复发性和/或难治性、复发性和新诊断的MM，现在两者都显示出作为维持治疗的前景。正在进行的主要转化研究工作包括改进的分类和个性化治疗;在其微环境中靶向肿瘤细胞的下一代药物的鉴定和验证;新型免疫疗法;基于合理的联合疗法;以及使用新的药剂来延迟或预防活动性MM的发展。这种靶向肿瘤微环境的范例已经将MM的中位生存期从3延长至7，8年，具有改善其他血液恶性肿瘤和实体瘤患者结局的巨大潜力。临床癌症研究; 17（6）; 1225-33。（C）2011年《非洲标准化评论》。
Multiple myeloma (MM) is an example of rapid bench-to-bedside translation in new drug development. Bortezomib and lenalidamide target the tumor cell in the bone marrow microenvironment to overcome drug resistance in laboratory and animal models; each is effective to treat relapsed and/or refractory, relapsed, and newly diagnosed MM, and both are now showing promise as maintenance therapy. Major ongoing translational research efforts include improved classification and personalized therapies; identification and validation of next-generation agents targeting the tumor cell in its microenvironment; novel immune therapies; rationally based combination therapies; and use of novel agents to delay or prevent development of active MM. This paradigm of targeting the tumor in its microenvironment has already extended median survival in MM from 3 to 7 to 8 years and has great potential to improve patient outcome in other hematologic malignancies and solid tumors as well. Clin Cancer Res; 17(6); 1225-33. (C)2011 AACR.